BIKAM and Dalton Medicinal Chemistry Expand and Renew Research Agreement
30-Oct-2009
- USA
Dalton Medicinal Chemistry will continue to utilize their proprietary insights to advance several novel classes of compounds against selected BIKAM targets. BIKAM will advance these agents with their growing cutting edge battery of biological assays and delivery methodologies.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.